NIH grants MSDC $1.1m to study MSDC-0602 in FLD tretament
MSDC-0602, an insulin sensitizer is selective for a molecular target, mTOT, which connects mitochondrial metabolism to important cell functions. Recent Phase 2a study in patients suffering with type
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.